First-in-class oral innate immune activator BXCL701 combined with pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) phenotype: Phase 2a final results.
Meeting Abstract
Aggarwal, Rahul Raj; Zhang, Jingsong; Zhu, Xinhua; Monk, Paul; Jones, Robert J.; Linch, Mark David; Costin, Dan; De Bono, Johann S.; Karsh, Lawrence Ivan; Petrylak, Daniel P.; Borderies, Pascal; Deshpande, Rashmi Majali; Hafeez, Amir; O'Neill, Vincent J.; Tagawa, Scott T.